Connecting linkedin

W1siziisimnvbxbpbgvkx3rozw1lx2fzc2v0cy9oyw1sew4td2lsbglhbxmvanbnl2jhbm5lci1kzwzhdwx0lwpvyi5qcgcixv0

Job

Senior Director Medical Affairs

  • Location

    New York

  • Sector:

    Life Sciences

  • Job type:

    Permanent

  • Salary:

    Negotiable

  • Contact:

    Caroline Candela

  • Contact email:

    c.candela@hamlynwilliams.com

  • Salary high:

    0

  • Salary low:

    0

  • Published:

    24 days ago

  • Expiry date:

    2020-11-25

  • Startdate:

    ASAP

A clinical- stage biotech with novel oncology platform is looking to build out their Medical Affairs function having received recent FDA fast-track designation. This position reports directly to the Chief Medical Officer

Requirements:

  • Trained Medical Doctor M.D., Board certified or elligible in Oncology, Hematology/Oncology, or related fied preferred.
  • 5+ years industry experience in clinical development required. Industry pexperience in intratumoral treatments preferred.
  • Excellent scientific record with experience in basic cancer research and/or oncology clinical trials within academic institutions or the pharmaceutical industry
  • Desire and ability to effectively participate within multi-disciplinary teams.

Responsibilities:

  • Leads medical affairs strategy for oncology pipeline
  • Contributes to selection of discovery compounds, design of development strategy and transition of compounds into late phase development.
  • Leads the interpretation of clinical results and makes appropriate recommendations in support of the overall strategy.
  • Contributes to the writing and review of reports submitted to regulatory agencies.
  • Builds relationships with key opinion leaders and principal investigators.
  • Contribute to corporate strategic and organizational initiatives.
  •  Leads and oversees the tactical development and strategic definition of clinical study programs, including protocol writing, interpretation of clinical data, and literature reviews.
  • Ensures that all clinical studies are in keeping with approved timelines, with potential obstacles identified and solutions implemented to avoid delays in clinical study execution.